Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis

Cerebrovascular Diseases - Tập 48 Số 1-2 - Trang 32-37 - 2019
A. Lurkin1, Laurent Derex1,2, Alexandra Fambrini3, Laurent Bertoletti1,4,3, Magali Epinat5, Patrick Mismetti1,4,3, Yesim Dargaud1,6
1Groupe d’Etude Multidisciplinaire sur les Maladies Thrombotiques (GEMMAT), Lyon, France
2Unité Neurovasculaire, Hôpital Neurologique Pierre Wertheimer, Lyon, France
3Médecine Vasculaire et Thérapeutique, Hôpital Nord, Saint-Etienne, France
4INSERM UMR 1059 SAINBIOSE, Université Jean-Monnet, Saint-Etienne, France
5Unité Neurovasculaire, Hôpital Nord, Saint Etienne, Saint-Etienne, France
6Unité d’Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Lyon, France

Tóm tắt

<b><i>Background:</i></b> Cerebral venous thrombosis (CVT) is an uncommon neurological condition usually treated with heparin followed by oral vitamin K antagonists (VKAs). In patients with venous thromboembolism (VTE), compared to VKAs, direct oral anticoagulants (DOACs) offer several advantages. However, there is little data concerning their use in managing CVT. <b><i>Aims:</i></b> This retrospective observational study pursued 2 objectives: (1) to investigate clinical characteristics of CVT patients treated with heparin + DOACs vs. heparin + standard treatment; (2) to compare clinical outcomes. <b><i>Methods:</i></b> Consecutive CVT patients recruited from January 2016 to March 2018 in 2 French university hospitals (Lyon, Saint-Etienne), and treated with DOACs or VKAs were identified. Radiological evolution, VTE, hemorrhagic events, and antithrombotic medication were recorded. Functional outcome was assessed by the modified Rankin scale score and venous recanalization was assessed by magnetic resonance imaging. <b><i>Results:</i></b> Overall, 41 patients were included: 25 (61%) received VKAs and 16 (39%) DOACs. We identified no clinical or radiological features explaining the physicians’ preference for a specific anticoagulation treatment, and age, initial clinical presentation, radiological severity, and individual risk factors thus unlikely guided the choice of anticoagulant. No DOAC patient exhibited clinical or radiological thrombosis aggravation, and the thrombosis completely vanished in 6 (40%). Two of the VKA-treated patients (28.6%) demonstrated complete venous recanalization, whereas 3 others experienced clinical or radiological aggravation versus baseline. There was no major bleeding leading to hospitalization in both groups. <b><i>Conclusion:</i></b> The collected data on DOAC efficacy and safety in CVT management appear encouraging, yet needs to be confirmed by larger prospective randomized clinical trials.

Từ khóa


Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Cerebrovascular Diseases

Tập 48 Số 1-2

32-37

Thông tin tác giả